Sector Expert: James Joyce
Jim Joyce is the founder of Exosome Sciences and founder, chairman and CEO of Aethlon Medical (AEMD:NASDAQ), which maintains majority ownership in Exosome Sciences. Under Joyce's leadership, Aethlon pioneered the creation of affinity biofiltration devices to treat life-threatening diseases. Time magazine recently named the Aethlon Hemopurifier® to be one of the "Top 25 Inventions" and one of "11 Remarkable Advances in Healthcare" based on the Hemopurifier's ability to address a broad-spectrum of viral pathogens, including the successful treatment of Ebola virus. In the field of exosome biology, Joyce has co-authored exosome-related publications and is co-inventor on exosome-specific patent submissions. Prior to founding Exosome Sciences and Aethlon Medical, he was managing director at James Joyce & Associates, founder and CEO of Mission Labs, Inc. and was a member of the Denver Broncos Football Club of the National Football League. Joyce is a graduate of the University of Maryland.
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals.
Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary (12/22/15)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD:NASDAQ), is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy (CTE), a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report, other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE.
Aethlon Medical's Biofiltration Platform Tackles Everything from Ebola to Cancer: CEO James Joyce (10/28/15)
Aethlon Medical Inc. has pioneered a novel biofiltration platform that was used effectively against Ebola in 2014. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. Aethlon CEO James "Jim" Joyce tells The Life Sciences Report how this device is helping transform modern healthcare.